Reata Pharmaceuticals

Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions
Fierce Pharma
Wed, 10/11/23 - 11:55 pm
Biogens
layoffs
Reata Pharmaceuticals
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
Fierce Pharma
Tue, 08/15/23 - 11:53 am
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Friedreich’s ataxia
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Motley Fool
Thu, 08/10/23 - 09:57 am
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Motley Fool
Tue, 08/1/23 - 11:55 am
Biogen
Reata Pharmaceuticals
M&A
Biogen to acquire rare disease drugmaker Reata for $7.3B
BioPharma Dive
Fri, 07/28/23 - 11:50 am
Biogen
Reata Pharmaceuticals
M&A
Friedreich's Ataxia
Biopharma stocks go back to bleak
EP Vantage
Thu, 04/6/23 - 09:51 am
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
FDA Approves First Therapy for Friedreich's Ataxia
BioSpace
Tue, 02/28/23 - 10:48 pm
Reata Pharmaceuticals
FDA
Friedreich's Ataxia
FDA scraps AdComm for Reata's rare disease candidate, leaving analysts squinting at the tea leaves
Fierce Biotech
Sun, 10/16/22 - 05:17 pm
Reata Pharmaceuticals
omaveloxolone
FDA
Friedreich's Ataxia
Reata’s ‘regulatory concerns’ turn into three-month delay on FDA decision for Friedreich’s ataxia drug
Endpoints
Tue, 08/9/22 - 10:27 am
Reata Pharmaceuticals
Friedreich's Ataxia
FDA
omaveloxolone
FDA regulatory roundup: two approvals, three rejections & one clinical hold
MedCity News
Sun, 03/6/22 - 11:08 pm
FDA
JNJ
CTI BioPharma
Gilead Sciences
Amryt Pharma
Reata Pharmaceuticals
FDA rejects Reata Pharma chronic kidney disease drug; new trial needed
MedCity News
Mon, 02/28/22 - 09:15 am
Reata Pharmaceuticals
Bardoxolone
Alport syndrome
kidney disease
FDA
FDA adcomm votes unanimously against Reata's potential Alport syndrome treatment
Endpoints
Wed, 12/8/21 - 11:41 pm
FDA
Reata Pharmaceuticals
Alport syndrome
Reata Pharmaceuticals Sees Hiccup in Filing for Approval of FA Drug
BioSpace
Wed, 08/12/20 - 12:11 am
Reata Pharmaceuticals
Friedreich's Ataxia
omaveloxolone
Reata Bags $350M As It Preps Rare Chronic Kidney Disease Drug For FDA
Xconomy
Thu, 06/11/20 - 10:42 pm
Reata Pharmaceuticals
kidney disease
Alport
chronic kidney disease
bardoxolone methyl
Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients
Reuters
Mon, 03/30/20 - 08:18 pm
Reata Pharmaceuticals
PAH
clinical trials
COVID-19
Reata Pharmaceuticals Just Raised $505 Million to Treat Orphan Diseases
Motley Fool
Tue, 11/26/19 - 10:29 am
Reata Pharmaceuticals
orphan diseases
omaveloxolone
Reata's bardoxolone offers promise in patients with rare kidney disorder
Endpoints
Tue, 11/12/19 - 10:22 am
Reata Pharmaceuticals
Bardoxolone
chronic kidney disease
Alport syndrome
Reata shocks analysts with pivotal win in Friedreich's ataxia
Fierce Biotech
Tue, 10/15/19 - 10:18 am
Reata Pharmaceuticals
omaveloxolone
Friedreich's Ataxia
clinical trials
AbbVie Stays Busy While Working to Complete Allergan Acquisition
BioSpace
Fri, 10/11/19 - 10:34 pm
AbbVie
Allergan
M&A
Skyrizi
Reata Pharmaceuticals
Reata buys drug rights back from AbbVie for $330M before readout
Biopharma Dive
Thu, 10/10/19 - 12:53 pm
Reata Pharmaceuticals
AbbVie
bardoxolone methyl

Pages